

Global Thematic Share Fund

Fund Focus - January 2022



Investment Strategy

The Fund generally invests in a broad selection of securities listed on foreign stock exchanges. The Fund will actively hedge up to 40% of the Fund's exposure to international currency back to Australian dollars.

Portfolio Characteristics

Funds Under Management	\$292.77m
Number of Holdings	107
Turnover Ratio %	18.36
Latest Distribution Date	30 June 2021
Latest Distribution Amount	0.0120
Benchmark	MSCI World (ex Australia) Accumulation Index in \$A (net dividend reinvested)

Fund Facts

APIR Code	ZUR0061AU
Inception Date	25 July 1997
Total Est. Management Cost %	0.99
Est. Transactional Op. Cost %	Nil
Buy/Sell Spread %	0.04
Distribution Frequency	Semi Annually
Underlying Fund Manager	Lazard Asset Management Pacific Co


Fund Performance After Fees*

	1 Month	3 Months	1 Year	3 Years	5 Years	Since Inception
Distribution	0.00	0.00	1.00	1.98	14.75	5.78
Growth	-3.66	0.59	18.57	16.27	0.78	1.67
Total	-3.66	0.59	19.57	18.25	15.53	7.45
Benchmark	-2.20	3.13	27.30	18.09	15.11	7.23

Market Exposure




Investment Growth (\$10,000)




Risk Reward

1 Feb 2017 to 31 Jan 2022



Portfolio Equity Sectors (%)



Top 10 Holdings (%)

	Weight	Benchmark
Alphabet Inc Common	2.28	2.76
Microsoft Corp Commo	2.21	3.83
Thermo Fisher Scient	1.32	0.39
Danaher Corp Common	1.30	0.32
Unitedhealth Group I	1.23	0.77
Laboratory Corp Of	1.22	0.00
Linde Plc Common Sto	1.21	0.28
Nutrien Ltd Common S	1.21	0.07
Bp Plc Common Stock	1.20	0.00
Diageo Plc Common St	1.20	0.00

Risk Statistics

1 Feb 2017 to 31 Jan 2022

Std Dev	10.01
Alpha	1.57
Beta	0.92
Sharpe Ratio (arith)	1.55
Up Capture Ratio	95.47
Down Capture Ratio	84.83
Currency Management %	0

Global Thematic Share Fund

Fund Focus - January 2022




Theme Weight %



● Asset Efficiency	8.60
● Bits of Chips	8.10
● Data, Networks & Profits	10.00
● Digital Runway	6.40
● Empowered Consumer	10.30
● Enduring Brands	9.70
● Energy Transitions	9.50
● Extreme Risks	6.30
● First World Health	12.10
● Software as a Standard	8.90
● Sustainable Solutions	8.50

Contribution by Theme %



Note: Total will not add up to 100%, the balancing item is cash

Market Commentary

Amid heightened volatility, world stocks prices slid in January as markets reset in nervous anticipation of changes in the global monetary landscape.

In the wake of the US Federal Reserve's (Fed) announcement last month that it would pull back on its extraordinary monetary support, all eyes were on the US central bank and its next move. With US inflation near a 40-year high, and amid indications that the Omicron coronavirus variant is considerably milder than earlier strains, investors worried that the Fed would have significant room to aggressively tackle surging prices. The Fed's announcement in late January that it was on track to raise interest rates in mid-March was expected; however, its unwillingness to commit to a pre-set course, thus opened the door to more frequent and potentially larger hikes than anticipated. This unnerved investors, who were fearful that raising interest rates too quickly or too much could have an adverse impact on corporate profits, consumer demand, and the fragile global economic recovery. Higher interest rates would also increase selling pressure on US government bonds, thereby driving yields upward and undercutting the appeal of stocks.

Fund Commentary

The Fund fell in January in absolute terms and underperformed the index return. There was significant dispersion in theme performance, as investors assessed the impact of a likely near-term interest hike by the Fed and the resultant yield pressure it would put on certain stocks. Themes discussed below are in descending order of contribution.

Digital Runway: ICICI Bank and HDFC rose on robust loan growth in India. Ping An traded higher, thanks to an easing of Chinese regulatory pressure. DBS advanced on higher interest rates. Prudential declined due to worries about China's ongoing zero-COVID policy.

Extreme Risks: Bank of America traded higher as part of larger gains made by US bank stocks, thanks to expectations of higher near-term interest rates, which would allow lenders to charge more on lucrative loans. Gold stocks declined on ongoing input cost pressures.

Energy Transitions: Oil producer stocks, led by BP and Total, climbed in sympathy with the rise in oil prices, due to tight supply demand. Vestas and Siemens Gamesa slid on concerns about logistics and cost pressures. Air Liquide and Linde faltered on broader market rotation.

Data, Networks, and Profits: FIS, Mastercard, and Visa all rose on encouraging spending data. Tencent traded higher on easing regulatory pressure. Wolters Kluwer receded due to a market rotation. Clarivate declined on management change and an accounting restatement.

Empowered Consumer: Activision rose on news that it was an acquisition target of Microsoft. Alibaba rose on easing of Chinese regulatory pressure. Sony retreated on Microsoft's acquisition of Activision.

Enduring Brands. Coca-Cola rose on data points highlighting the company's pricing power. Pernod Ricard and Remy Cointreau declined on market rotation away from perceived "pandemic winners."

Software as a Standard: All holdings declined led by Accenture, SAP. Intuit fell on market rotation away from so-called "pandemic winners."

Bits of Chips: Most holdings declined led by Keysight, Applied Materials and TE Connectivity. Aptiv faltered on cyclical weakness and ongoing supply constraints.

Asset Efficiency: Deere rose on the announcement of fully automated tractors. Rockwell, Hexagon, and Schneider traded lower on weakness in industrials linked to supply chain issues, and inflation.

Sustainable Solutions: All holdings declined, led by Azek on rotation from perceived "pandemic winners" and the potential impact of rising rates on housing demand.

First World Health: Olympus rose on expectations for a recovery in procedure demand. Zoetis, Siemens Healthineers, Thermo Fisher, and Danaher declined on market rotation. Olympus Corp was added to the Fund in January as the company's status as a leading provider of endoscopy and therapeutic solutions make it a good fit for First World Health theme. Both endoscopy systems and therapeutic solutions are structurally high-growth industries. There is a high barrier to entry in both businesses and the company has multiple avenues for growth.

* Performance returns quoted are compound rates of return calculated on exit prices and assume reinvestment of distributions. Returns are calculated net of all ongoing fees and any taxes payable by the fund. Total return includes both growth and distribution returns. Growth return is the change in exit price over the relevant period. The benchmark return shown is a gross return. Please note that figures shown are rounded to one decimal place, therefore some rounding errors may occur.

^ The Estimated Total Management Cost of 0.99% includes an Estimated Performance Fee of 0% and Estimated Indirect Costs of 0.01%.

Past performance is not a reliable indicator of future performance.

This report is issued by Zurich Investment Management Limited ABN: 56 063 278 400, AFSL: 232511, GIIN: FVHHKJ.00012.ME.036 : . The information in the report has been derived from sources reasonably believed to be reliable and accurate and is to be used for research purposes only. Subject to law, none of the companies of the Zurich Financial Services Australia Limited Group, nor their directors or employees, gives any representation or warranty as to the reliability, accuracy or completeness of the information, nor accepts any responsibility arising in any way (including by reason of negligence) from errors in or omissions from, the information provided. A Product Disclosure Statement (PDS) for the Fund is available and can be obtained by calling Zurich Investments on 131 551. The PDS should be considered in deciding whether to acquire, or to continue to hold, an investment in the fund. This information is of a general nature only and does not take into account the investment objectives, financial situation or particular needs of any investor and should not be taken as a securities or stock recommendation. These factors should be considered before any investment decision is made in relation to the fund. Furthermore, this product has been designed to meet certain objectives, financial situations and needs, which are described in our Target Market Determination available at zurich.com.au/tmd PIRD-018221-2022